Differential Drug Resistance Acquisition in HIV-1 of Subtypes B and C Authors: Esmeralda A. J. M. Soares, André F. A. Santos, Thatiana M. Sousa, Eduardo Sprinz, Ana M. B. Martinez, Jussara Silveira, Amilcar Tanuri, Marcelo A. Soares Published: 2007, PLOS ONE DOI: 10.1371/journal.pone.0000730 ABSTRACT Subtype C is the most prevalent HIV-1 subtype in the world, mainly in countries with the highest HIV prevalence. However, few studies have evaluated the impact of antiretroviral therapy on this subtype. In southern Brazil, the first developing country to offer free and universal treatment, subtypes B and C co-circulate with equal prevalence, allowing for an extensive evaluation of this issue. Viral RNA of 160 HIV-1+ patients was extracted, and the protease and reverse transcriptase genes were sequenced, subtyped and analyzed for ARV mutations. Sequences were grouped by subtype, and matched to type (PI, NRTI and NNRTI) and time of ARV exposure. Statistical analyses were performed to compare differences in the frequency of ARV-associated mutations. There were no significant differences in time of treatment between subtypes B and C groups, although they showed distinct proportions of resistant strains at different intervals for two of three ARV classes. For PI, 26% of subtype B strains were resistant, compared to only 8% in subtype C ( p  = 0.0288, Fisher's exact test). For NRTI, 54% of subtype B strains were resistant versus 23% of subtype C ( p  = 0.0012). Differences were significant from 4 years of exposure, and remained so until the last time point analyzed. The differences observed between both subtypes were independent of time under rebound viremia in cases of virologic failure and of the number of HAART regimens used by treated patients. Our results pointed out to a lower rate of accumulation of mutations conferring resistance to ARV in subtype C than in subtype B. These findings are of crucial importance for current initiatives of ARV therapy roll-out in developing countries, where subtype is C prevalent. INTRODUCTION The genetic diversity of human immunodeficiency virus type 1 (HIV-1) allows for its classification in several groups, subtypes, sub-subtypes and circulating recombinant forms (CRF) [1] . To date, 9 known subtypes and at least 34 CRF are heterogeneously distributed around the world. While subtype B predominates in developed countries of Western Europe and U.S., other (non-B) subtypes or CRF account for the majority of infections in the developing world [2] . Interestingly, subtype C is responsible for 50% of global HIV infections [2] , in countries with the highest known prevalence (in sub-Saharan Africa), and with large populations, like India [3] , [4] . An increasing body of experimental evidence suggested that different HIV-1 subtypes might exhibit disparate biological behaviors, and might respond differently to diagnostic, immunologic and therapeutic interventions [5] – [7] . With respect to HIV antiretroviral (ARV) treatment, recent studies identified subtype-specific differences in viral susceptibility to specific drugs [8] , [9] and in signature mutations selected by treatment [10] – [12] . An important problem, in this scenario, is whether HIV-1 subtypes may differ in the rate of fixation of mutations conferring drug resistance in individuals under ARV therapy, a point recently addressed in a single report [13] . As Brazil exhibits a heterogeneous HIV-1 subtype distribution [14] , [15] and a history of universal and free access to ARV therapy since 1996 [16] , it represents an appropriate setting for retrospectively analyzing the rate of fixation of mutations conferring drug resistance under specific ARV class exposure, in different subtypes. In particular, we selected the southernmost state of Brazil, Rio Grande do Sul, as study site because it is characterized by an equal distribution of B and C subtypes [17] , [18] co-circulating in individuals under similar socio-demographic conditions. In this report, we found that subtype C is less prone to fix mutations conferring drug resistance over time when compared to subtype B counterparts subjected to the same type and length of ARV drug exposure, in two of three ARV classes. METHODS Regularly followed patients, at two public health system hospitals in the state of Rio Grande do Sul (Hospital de Clínicas de Porto Alegre and Hospital Universitário do Rio Grande), participated in this study. One hundred and sixty patients were initially enrolled. Eligibility criteria included age above 18 years, current exposure to ARV therapy at time of sampling and availability of all clinical, laboratory (CD4 + T-cell counts and HIV viral load) and treatment histories. Viral load measurements were conducted with the Quantiplex HIV-1 RNA 2.0 Assay (Bayer Diagnostics, Tarrytown, NY, U.S.). Only patients with self-reported adherence to therapy during all treatment periods were included in analyses. Following written informed consents (provided by 100% of participants), plasma specimens were collected and available medical records were reviewed. All sample collections were conducted from July 2002 to January 2003. This study was approved by the Internal Review Boards from both Institutions, the Comitê de Ética em Pesquisa do Hospital de Clínicas de Porto Alegre and the Comitê de Ética em Pesquisa na Área de Saúde da Fundação Universidade Federal do Rio Grande . HIV-1 MOLECULAR CHARACTERIZATION AND DRUG RESISTANCE ANALYSIS Viral RNA was extracted from plasma and complementary DNA synthesis was carried out with random primers as previously described [19] . Nested polymerase chain-reactions (PCR) were conducted with specific primers. The entire protease region (PR) and the first 225 codons of reverse transcriptase (RT) were amplified, purified with the Qiagen PCR purification kit (QIAGEN, Valencia, CA) and sequenced in an ABI3100 automated sequencer (Applied Biosystems, Foster City, CA). Sequences were aligned with SeqMan (DNAStar, Madison, WI) and manually edited. Edited sequences were subsequently aligned, with ClustalW [20] , to reference sequences representative of all HIV-1 subtypes available at the Los Alamos database ( hiv-web.lanl.gov ). Aligned sequences were subjected to phylogenetic analyses by neighbor-joining and Kimura 2-parameter model of the MEGA 3.0 package for inference of HIV-1 subtypes [21] . Identification of antiretroviral resistant mutations in PR and RT genes was carried out following electronic submission to the Stanford University database ( hivdb.stanford.edu ) [22] . Mutations were recorded according to the International AIDS Society-USA consensus [23] . Sequence data were submitted to the GenBank with accession numbers AY275719-AY275807, AY390079-AY390081, AY390178-AY390190, DQ190959-DQ191030, DQ343964-DQ344016, and DQ659454-DQ659487. DATA GROUPS AND STATISTICAL ANALYSES Demographic and clinical data from patients (age, gender, time of HIV diagnosis, CD4 T-cell counts, HIV viral load, CDC immune and clinical staging and treatment status and time of treatment) were compiled for each subtype (B and C) group and differences were analyzed with Student's t -test or Fisher's exact test. Sequences were grouped according to their assigned HIV-1 subtype, and further separated according to type of ARV exposure, nucleoside/nucleotide RT, non-nucleoside RT or protease inhibitors (NRTI, NNRTI and PI, respectively). Finally, viral sequences were further grouped according to time of ARV exposure (in 12-month periods) within each ARV class. Cumulative curves of proportions of mutant viruses within each group over ARV exposure time were plotted for each subtype (B and C). Significant differences in the proportion of mutants at each time point were evaluated by one-tailed Fisher's exact tests, with significance level  = 0.05. The same analysis was also conducted for patients subjected exclusively to HAART, to avoid confounding factors of drug resistance generation by sub-optimal regimens (mono and/or dual therapy). Additionally, we have compared the proportion of patients subjected to one or more than one HAART regimen, as well those that received mono and/or dual therapy prior to HAART in both subtypes. The average number of mutations per genome, as well as the proportion of resistant strains in those three groups was also compared in both subtypes. Exposure times to individual antiretrovirals were also compiled for each subtype group for evaluating differences with respect to specific drugs. We have also assessed the impact of length of rebound viremia in treated patients on the acquisition of drug resistance mutations in both subtypes, by comparing the average time of rebound viremia in both groups through Student's t test. The proportion of resistant viruses among those patients with rebound viremia was also compared through Fisher's exact test. Finally, we have also compared the proportion of patients reaching undetectable viral load after HAART initiation over time in both subtype groups by Fisher's exact test. RESULTS One hundred and sixty patients with known ARV treatment history were screened for infecting HIV-1 subtype by RT-PCR, by sequence and phylogenetic analyses of partial pol sequences. Of these, 136 were infected with either subtype B (n = 84) or C (n = 52), which were selected for further analysis. The 24 remaining viral isolates corresponded to subtype F1 (n = 11), subtype D (n = 4), and mosaic forms (n = 9). Table 1 summarizes major demographic and clinical parameters for subtype B- and C-infected groups. Of these parameters, time elapsed from diagnosis to sample collection differed significantly between both groups, being shorter for subtype C-infected patients ( p  = 0.013; Student's t-test). The proportion of patients in each subtype group classified in CDC clinical stage C also differed significantly ( p  = 0.05; Fisher's exact test). Finally, subtype B-infected patients showed lower CD4 T-cell counts than subtype C at HAART initiation ( p  = 0.003; Table 1 ). Bold p values are significant at the 0.05 level All amino acid-deduced pol sequences from treated patients were analyzed for drug resistance mutations according the IAS-USA consensus [23] . Most of the RTI- and PI-associated mutations occurred in both subtype groups, suggesting that qualitative patterns of drug resistance acquisition were similar. Some RTI (K65R, L74V) and PI (D30N, M46I/L, I84V) mutations were only seen in subtype B isolates. Conversely, one multi-NRTI resistant genotype (A62V, V75I, F116Y and Q151M) was found among subtype C isolates. Of note, the thymidine analogue mutations M41L, L210W and the 3TC-associated mutation M184V/I, as well as the PI mutation L90M, were significantly more frequent in subtype B isolates ( p <0.05, data not shown). Interestingly, when both patient groups were analyzed with respect to the number of average mutations per viral genome, subtype B showed higher numbers for all ARV classes, but only the difference for protease inhibitors was found significant (0.6 mutations per genome in subtype B versus 0.12 in subtype C; p <0.01, Student's t test). This higher accumulation of mutations in subtype B isolates could not be explained by longer exposure to ARV therapy because it did not differ from subtype C exposure, either per class or globally ( Table 1 ). Despite similar times of total ARV exposure, subtype B might have been exposed to mono and dual therapy for a longer time because this subtype has been circulating in Brazil for a longer period than subtype C, at a time when these regimens were common. This could have selected mutations faster in subtype B than in C. However, analysis of previous time of exposure to mono and/or dual therapy in both groups failed to show significant differences ( p  = 0.9629, Student´s t test, data not shown). We further examined the lower accumulation of drug resistance mutations in subtype C isolates compared to subtype B counterparts by analyzing mutations in individual ARV classes. For PI, 38% of subtype B isolates presented at least one primary resistance mutation versus only 8% of subtype C isolates ( p  = 0.0037, Fisher's exact test). For NRTI, 56% of subtype B isolates presented primary resistance versus 23% of subtype C isolates ( p  = 0.0009, Fisher's exact test). For NNRTI, no differences in the proportion of resistant isolates were found between subtypes. In addition to the ARV class exposure, all patients in both groups had their complete treatment history assessed and were stratified according to time of exposure to each ARV class. Patients were cumulatively pooled in increasing time periods, and the percentage of strains carrying primary mutations was compared in both subtype groups ( Figure 1 shows these comparisons for each ARV class). For NRTI-related mutations, subtype C viruses differed significantly from subtype B from 4 year-exposure, and this difference steadily increased to 9 year-exposure ( Figure 1A ). At this point, 54% of subtype B viruses harbored NRTI-related mutations, whereas less than half (23%) of subtype C viruses carried these mutations ( p  = 0.0012, Fisher's exact test). Protease resistance mutations occurred significantly at higher levels in subtype B already by 4 years of PI exposure, and also remained significantly higher for up to 5 years (26% in subtype B versus 8% in subtype C; p  = 0.0288, Fisher's exact test; Figure 1C ). In agreement with previous analyses, NNRTI mutations did not differ significantly in both subtype groups, at least to 4 years of exposure, the longest available period ( Figure 1B ). Different treatment exposure periods (in months) were plotted for each subtype and for each ARV drug class. (A) NRTI, (B) NNRTI, (C) PI. Black asterisks denote significance in the difference of proportions between subtypes B and C at the 0.05 p value level. Despite that subtype B and C-infected groups did not differ significantly in time of mono and/or dual therapy previous to HAART, we further restricted our analyses to patients exclusively subjected to HAART ( Figure 2 ). The acquisition of resistance mutations for all ARV classes was identical to those found in global analyses, indicating that NRTI- and PI-associated mutations accumulated faster for subtype B from year 4 of exposure, while NNRTI mutations did not differ between both groups. Different treatment exposure periods (in months) were plotted for each subtype and for each ARV drug class. (A) NRTI, (B) NNRTI, (C) PI. Black asterisks denote significance in the difference of proportions between subtypes B and C at the 0.05 p value level. It was possible that the number of resistance mutations was associated with a differential use of sequential HAART regimens. To evaluate this, we have compared patients with one or multiple HAART regimens in each subtype group with respect to the average number of mutations per genome and the proportion of resistant strains. Despite the fact that similar proportions of patients were subjected to multiple regimens in both groups (52% of subtype B versus 42% of subtype C, p = 0.11), subtype C had lower proportion of resistant strains and lower average number of mutations in all compared treatment groups ( Table 2 ). Even in patients previously subjected to mono and/or dual therapy, the number of resistant strains was significantly higher for subtype B ( Table 2 ). Statistically significant p-values (<0.05) are in boldface Number of patients with resistance/total Fisher's exact test Student's t test We have also evaluated the role of each individual ARV drug in the appearance of drug-associated mutations. We calculated the time of exposure to individual ARV in both subtype groups, taking into account the global patient dataset, as well as for those only subjected to HAART ( Table 3 ). Differences in time of exposure to D4T, 3TC and NFV were seen in the global dataset, but these differences only remained significant for NFV when analyzing patients exclusively subjected to HAART. This demonstrated that in these patients, without significant differences in exposure to D4T and 3TC, there was a higher accumulation of NRTI-associated mutations in subtype B ( Figure 2A ). The antiretroviral drugs tenofovir and abacavir were not available to patients in the Public Health System at the time of survey Values left to the bar correspond to the total treated patients analyzed in the study; those at right represent patients which were only subjected to HAART therapy Comparative T -test values in bold are those significant at the 0.05 level Since we observed a longer NFV exposure in subtype B patients, this ARV might explain the differences observed between subtype groups in the PI class ( Figures 1C and 2C ). In fact, half (10/21) of subtype B-infected patients under NFV presented NFV-associated mutations, while none of the subtype C isolates (0/8), under NFV exposure, showed these mutations. For this reason, we analyzed PI-associated mutations in all patients under NFV as PI component of their HAART regimen. This showed that subtype B still accumulated more NFV-associated mutations (primary or secondary) even when matching time of exposure between subtype groups ( Figure 3 ). Around 12 months of NFV exposure, some 10% of subtype B strains already carried NFV-associated mutations, while none of subtype C strains was resistant to NFV. By 24 and 36 months, approximately 30% of subtype B strains already carried NFV mutations, and differences in the proportion of resistant strains was already statistically significant ( p  = 0.05; Figure 3 ). Thus, despite NFV had been used more extensively in subtype B-infected subjects, it resistance mutations were positively selected more rapidly when matching exposure times were analyzed. Different treatment exposure periods (in months) for that drug were plotted for each subtype. Black asterisks denote significance in the difference of proportions between subtypes B and C at the 0.05 p value level. We have also investigated the impact of rebound viremia time on the accumulation of drug resistance. It was plausible that subtype B patients could have accumulated more mutations because they have had failed therapy for longer than those infected with subtype C. We found 24 subtype B- and 17 subtype C-infected patients with rebound viremia. We have calculated the average time of rebound viremia for each subtype group, and found that they do not differ significantly (15.6 months for subtype B and 19 months for subtype C). Interestingly, we found that the proportion of those patients carrying drug resistant viruses was significantly higher for subtype B (46%) than for subtype C (18%) (p = 0.048, Fisher's exact test). We have also checked the proportion of subtype B- and C-infected patients who had undetectable VLs over time of therapy, and they did not differ significantly at any time point, except for the initial suppression period (until 8 months after HAART initiation). At that time, the subtype C group had 79% of patients with undetectable VL, compared to only 52% of the subtype B group (p = 0.04, Fisher's exact test). TABLE: Demographic and clinical characteristics of HIV-1-positive treated patient groups infected with B and C subtypes. SUBTYPE B (n = 84) SUBTYPE C (n = 52) p value Age (yr/SD) 40.59 (10.86) 40 (12.51) 0.779 Gender (%) 0.131 Male 52 (62) 29 (58) Female 32 (38) 21 (42) Average time of diagnosis (yr/SD) 6.42 (3.88) 4.93 (3.02) 0.013 * CDC Clinical Stage (%) A 23 (27.71) 16 (31.38) 0.139 B 20 (24.10) 17 (33.33) 0.080 C 40 (48.19) 18 (35.29) 0.050 CDC Immune Stage (%) 1 19 (22.62) 11 (21.57) 0.170 2 40 (47.62) 23 (47.06) 0.142 3 25 (29.76) 15 (31.37) 0.154 Average CD4 T-cell counts at HAART initiation (SD) 135 (108) 254 (154) 0.003 Average CD4 T-cell counts at sample collection (SD) 334 (212) 334 (195) 0.937 Median log10 viral RNA prior to HAART initiation 5.2 5.0 0.975 Median log10 viral RNA at sample collection 2.6 2.0 0.198 Undetectable VL (%) (<80 copies/ml plasma) 28 (33.7) 22 (44.8) 0.065 Average time of ARV treatment (yr/SD) NRTI/Total 3.58 (2.18) 2.97 (2.15) 0.116 NNRTI 1.8 (0.98) 1.49 (0.99) 0.187 PI 2.72 (1.83) 2.59 (1.4) 0.687 TABLE: Comparison of drug resistance mutation acquisition between subtype B- and C-infected patients under different therapeutic regimens. Subtype B Subtype C p-value One HAART Regimen Proportion of isolates with at least one primary resistance mutation 33% (8/24) a 9.5% (2/21) 0.048 b Average number of drug resistance mutations per isolate (SD) 0.5 (0.78) 0.1 (0.3) 0.025 c Multiple HAART Regimens Proportion of isolates with at least one primary resistance mutation 62% (16/26) 20% (03/15) 0.001 Average number of drug resistance mutations per isolate (SD) 1.8 (3) 0.4 (0.8) 0.027 Previous mono- and/or dual therapy Proportion of isolates with at least one primary resistance mutation 56% (15/27) 25% (04/16) 0.039 Average number of drug resistance mutations per isolate (SD) 2.4 (2.9) 1.1 (2.4) 0.130 TABLE: Mean time of drug exposure in months for each HIV-1 subtype-infected group. Drug £ Subtype B Subtype C T-test Total/HAART # Total/HAART Total/HAART AZT 27.91/20.98 28.36/19.27 0.9043/0.6327 DDI 24.24/18.58 22.57/16.83 0.7206/0.4501 D4T 27.3/27.6 19/20.1 0.0218 * / 0.1375 3TC 27.6/24.4 21.4/19.5 0.0304 /0.1086 DDC 15.17/17.25 20.75/29.67 0.3494/0.3236 NFV 24.52/23.33 15.61/11.4 0.0092/0.0052 RTV 19.03/15.69 15.32/14.45 0.3227/0.7425 IDV 19.71/14.82 22.4/24.58 0.5349/0.1080 SQV 20.29/16.17 18.44/23.33 0.6961/0.3945 LPV 8.44/5.75 7.38/7.8 0.6887/0.8749 NVP 18.88/20 22.11/23.4 0.6515/0.7590 EFV 18.41/18.45 13.79/12.52 0.0781/0.0662 DISCUSSION The impact of ARV treatment on different HIV-1 subtypes and CRF is an issue of paramount concern associated to the introduction of treatment in developing countries. To date, however, scarce data are available on the impact of ARV in HIV-1 of non-B subtypes, which paradoxically account for almost 90% of all HIV infections in the world. Southern Brazil represents an ideal setting for assessing this question because subtypes B (the most studied) and C (the most prevalent) co-circulate in very similar frequencies in the same population [15] , [17] , [18] . Our group has previously shown that subtype C was introduced in Brazil later than subtype B [15] , [18] , [24] , in agreement with our observation of a shorter time of diagnosis for individuals infected with subtype C ( Table 1 ). Although the HIV subtype B epidemic is older, the time of treatment did not differ significantly between B and C subtypes for all drug classes ( Table 1 ). When analyzing the rate of accumulation of mutations conferring drug resistance over time for each major ARV class, subtype C viruses apparently acquired a lower number of mutations than subtype B for PI and NRTI, but not for NNRTI. We ruled out the possibility that previous exposure to mono- or dual-therapy in subtype B-infected patients (affected by an older epidemic) might explain these differences. To further investigate the rate of accumulation of mutations, we stratified subtype groups by time of therapy at 12 month-intervals. Here again, different rates between subtypes B and C were observed, for PI and NRTI mutations, but not for NNRTI. Our data were further confirmed by similar analyses in patients exclusively subjected to HAART. In this setting, we definitively excluded the possibility that previous mono and/or dual therapy accounted for these differences. Of note, HAART was universally initiated in Brazil with the introduction of PI in 1996, when the prevalence of subtypes B and C were already very similar [17] , [18] . We ruled out that time of exposure to individual ARV drugs, rather than ARV classes, accounted for different mutation rates between subtypes B and C. In fact, analysis of the global dataset showed that D4T, 3TC and NFV were more extensively used in subtype B patients ( Table 3 ) but the significance of D4T and 3TC exposure disappeared when analysis was restricted to HAART patients. This provided strong evidence that differences in NRTI-related mutations, still present in HAART patients, could not be attributed to a differential exposure to these drugs. As the use of NFV was significantly higher in subtype B isolates, we carried out separate analysis of the time of exposure to this drug matching exposure time. This analysis showed that subtype B accumulated NFV-related mutations more rapidly than subtype C. We have also ruled out the impact of treatment failure time on the increased drug resistance accumulation in subtype B. Both subtypes had similar rebound viremia times, but subtype B retained a higher proportion of resistant strains in failed individuals. The proportion of virological success (undetectable viral load, uVL) between subtype groups was similar in all time periods after HAART initiation, with the exception of the period spanning 5–8 months of therapy, where a higher proportion of subtype C had more patients with uVL. The use of distinct drug regimens (single or multiple HAART, or previous use of mono and/or dual therapy) did not seem to influence the higher rates of drug resistance acquisition in subtype B compared to C. For all types of ARV exposure, the proportion of resistant strains and the average number of mutations per genome was lower in subtype C-infected patients, with exception of patients subjected to mono/dual therapy. Our observations were unexpected and, to some extent paradoxical, since all ARV drugs were designed for subtype B, which predominates in developed countries [2] . Furthermore, the presence of polymorphisms in non-B subtypes, which are considered as secondary resistance mutations for subtype B [25] – [27] , supports the proposition that the acquisition of resistance might be enhanced in non-B subtypes. Holguin et al . [28] showed that these polymorphisms do not alter susceptibility of non-B subtypes to ARV drugs, while other authors have reported such differences, pointing out to the increased susceptibility of some non-B subtypes to some ARV [29] , [30] . Genotypic analyses of subtype B- and C-infected patients undergoing HAART failure in Israel showed several drug resistance mutations with higher frequency in subtype B viruses [31] . This study supported the hypothesis that subtype C accumulates resistance mutations at lower levels than subtype B. In our study, NNRTI was the only ARV class for which subtype C did not differ from subtype B with respect to the rate of acquisition of drug resistance mutations. Evidence that NNRTI-related mutations appeared at a higher rate in subtype C was previously reported [13] , in agreement with our results. A straightforward explanation for the findings herein reported can not be provided in view of the complexity of viral biology. Few studies are available on differences between group M subtypes in response to ARV. Recent studies postulated that different subtype-specific genetic barriers might be operating in the development of drug resistance [10] , [32] . Accordingly, some subtypes might accumulate resistance at different rates than subtype B at definite amino acid positions in PR and RT. Approximately 30% of subtype C presented a higher genetic barrier for acquiring mutation L210W versus 11% among subtype B viruses [32] , although differences at this position, per se , cannot explain the observed differences for NRTI. It is also conceivable that subtype C might accumulate fewer mutations because is more susceptible to the ARV drugs currently in use, as suggested for other non-B subtypes [29] , [30] . In fact, Gonzales et al . [7] showed that subtype C strains from Brazil and Africa were naturally hypersusceptible to the PI lopinavir. Moreover, subtypes may be operating under different evolutionary pressures when acquiring specific drug resistance mutations, as demonstrated for the D30N NFV-associated mutation in subtype C [11] . We cannot completely rule out the possibility that we have neglected potentially new, subtype C-specific drug resistance mutations in our analyses. A larger study comparing subtype C-infected drug-naïve and experienced patients identified three new putative positions (two in PR and one in RT) [26] . However, the phenotypic and clinical impact of changes at these codons is yet to be determined. So far, only mutation 89I/V was found associated with PI treatment for subtypes C, F and G [19] , but this was stated as a secondary mutation since it does not confer resistance per se . Alternatively, we may speculate that intrinsic fitness and replicative capacity of subtypes might account for their ability of accumulating mutations in the infected host. In this respect, it has been shown that subtype C is the least fit of all HIV-1 group M subtypes in competition assays carried out in peripheral blood mononuclear cells, independently of viral tropism [33] , [34] . Despite the fact that the lower accumulation of drug resistance mutations in HIV-1 subtype C has not been elucidated, our observations are highly relevant for international treatment roll-out initiatives aiming to extend ARV protocols to developing countries. These are particularly valid for countries of sub-Saharan Africa, which concentrate most of the HIV-infected individuals in the world, mainly by subtype C. Our data may be useful for an aggressive initiation and expansion of ARV therapy in the developing world. REFERENCES [1] Robertson DL Anderson JP Bradac JA Carr JK Foley B 2000 HIV-1 nomenclature proposal. Science 288 55 56 [2] Hemelaar J Gouws E Ghys PD Osmanov S 2006 Global and regional distribution of HIV-1 genetics subtypes and recombinants in 2004. AIDS 20 W13 W23 [3] Van Harmelen JH Van der Ryst E Loubser AS York D Madurai S 1999 A predominantly HIV-1 subtype C-restricted epidemic in South African urban populations. AIDS Res Hum Retroviruses 15 395 398 [4] Shankarappa R Chatterjee R Learn GH Neogi D Ding M Roy P 2001 Human immunodeficiency virus type 1 env sequences from Calcutta in Estearn India: identification of features that distinguish subtype C sequences in India from other subtype C sequences. J Virol 75 10479 10487 [5] Jeeninga RE Hoogenkamp M Armand-Ugon M de Baar M Verhoef K 2000 Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. J Virol 74 3740 3751 [6] Renjifo B Gilbert P Chaplin B Msamanga G Mwakagile D 2004 Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS 18 1629 1636 [7] Gonzalez LMF Brindeiro RM Tarin M Calazans A Soares MA 2003 The subtype C of human immunodeficiency virus type 1 protease presents an in vitro hypersusceptibility to protease inhibitor Lopinavir. Antimicrob Agents Chemother 47 2817 2822 [8] Carmona R Perez-Alvarez L Munoz M Casado G Delgado E 2005 Natural resistance-associated mutations to enfivurtite (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients. J Clin Virol 32 248 253 [9] Brenner B Turner D Oliveira M Moisi D Detorio M 2003 A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17 F1 F5 [10] Dumans AT Soares MA Machado ES Hue S Brindeiro RM 2004 Synounymous genetic polymorphisms within Brazilian human immunodeficiency vírus type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis 189 1232 1238 [11] Gonzalez LM Brindeiro RM Aguiar RS Pereira HS Abreu CM 2004 Impact of nelfinavir resistance mutations on in vitro phenotype, fitness and replication capacity of human immunodeficiency vírus type with B and C proteases. Antimicrob Agents Chemother 48 3552 3555 [12] Abecasis AB Deforche K Snoeck J Bacheler LT McKenna P 2005 Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 19 1799 1806 [13] Grossman Z Istomin V Averbuch D Lorber M Risenberg K 2004 Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 18 909 915 [14] Brindeiro RM Diaz RS Sabino EC Morgado MG Pires IL 2003 Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17 1063 1069 [15] Soares MA De Oliveira T Brindeiro RM Diaz RS Sabino EC 2003 A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil. AIDS 17 11 21 [16] Teixeira PR Vitoria MA Barcarolo J 2004 Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS 18 Suppl 3 S5 S7 [17] Soares EA Santos RP Pellegrini JA Sprinz E Tanuri A 2003 Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J Acquir Immune Defic Syndr 34 520 526 [18] Soares EA Martinez AM Souza TM Santos AF Hora VD 2005 HIV-1 subtype C dissemination in southern Brazil. AIDS 19 Suppl 4 S81 S86 [19] Stuyver L Wyseur A Rombout A Louwagie J Scarcez T 1997 Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 41 284 291 [20] Thompson JD Higgins DG Gibson TJ 1994 CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22 4673 4680 [21] Kumar S Tamura K Nei M 2004 MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 5 150 163 [22] Rhee SY Gonzales MJ Kantor R Betts BJ Ravela J 2003 Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 31 298 303 [23] Johnson VA Brun-Vezinet F Clotet B Kuritzkes DR Pillay D 2006 Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 14 125 130 [24] Salemi M de Oliveira T Soares MA Pybus O Dumans AT 2005 Different epidemic potentials of the HIV-1B and C subtypes. J Mol Evol 60 598 605 [25] Pieniazek D Rayfield M Hu DJ Nkengasong J Wiktor SZ 2000 Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 14 1489 1495 [26] Kantor R Katzenstein DA Efron B Carvalho AP Wynhoven B 2005 Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2 e112 [27] Kantor R 2006 Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 19 594 606 [28] Holguin A Paxinos E Hertogs K Womac C Soriano V 2004 Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol 31 215 220 [29] Abecasis AB Deforche K Bacheler LT McKenna P Carvalho AP 2006 Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir ther 11 581 589 [30] Vergne L Stuyver L Van Houtte Butel C Delaporte E 2006 Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naïve patients. J Clin Virol 36 43 49 [31] Grossman Z Vardinon N Chemtob D Alkan ML Bentwich Z 2001 Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 15 1453 1460 [32] van de Vijver DA Wensing AM Angarano G Asjo B Balotta C 2006 The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41 352 360 [33] Arien KK Vanham G Arts EJ 2007 Is HIV-1 evolving to a less virulent form in humans? Nat Rev Micriobiol 5 141 151 [34] Arien KK Abraha A Quinones-Mateu ME Kestens L Vanham G 2005 The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 79 8979 8990